The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
510
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigational Site
Phoenix, Arizona, United States
Investigational Site
Phoenix, Arizona, United States
Unnamed facility
Sun City, Arizona, United States
Investigational Site
Tucson, Arizona, United States
Investigational Site
Little Rock, Arkansas, United States
Investigational Site
Little Rock, Arkansas, United States
Investigational Site
Fresno, California, United States
Investigational Site
Irvine, California, United States
Investigational Site
Orange, California, United States
Investigational Site
San Francisco, California, United States
...and 74 more locations